FDA has announced it is taking steps to ensure that certain diagnostic tests are accurate, consistent and reliable.
FDA has announced it is taking steps to ensure that certain diagnostic tests are accurate, consistent and reliable.
The Agency is first issuing a final guidance on the development, review and approval or clearance of companion diagnostics, which are commonly used to detect certain types of gene-based cancers.
Second, it will publish a risk-based oversight framework for laboratory developed tests (LDTs) designed, manufactured and used within a single laboratory. They include some genetic tests and tests that are used by healthcare professionals to guide medical treatment for their patients. The FDA already oversees direct-to-consumer tests regardless of whether they are LDTs or traditional diagnostics.
The companion diagnostics guidance is intended to help companies identify the need for these tests during the earliest stages of drug development and to plan for the development of a drug and a companion test at the same time. The goal of the final guidance is “to stimulate early collaborations that will result in faster access to promising new treatments for patients living with serious and life-threatening diseases”.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.